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Outcomes From Conservative Treatment
of Shoulder Idiopathic Adhesive Capsulitis
and Factors Associated With Developing
Contralateral Disease
Joseph D. Lamplot,* MD, Olivia Lillegraven,* BA, and Robert H. Brophy,*† MD
Investigation performed at the Department of Orthopaedic Surgery, Washington University
School of Medicine, St Louis, Missouri, USA
Background: Idiopathic adhesive capsulitis is a common condition resulting in painful multidirectional restriction of motion without
other identifiable shoulder abnormality. First-line therapies for this condition are nonoperative, but limited data are available
regarding which treatments are most effective. Factors associated with contralateral disease are not well established.
Hypothesis: Younger patients will have a better response to treatments, and older patients and patients with diabetes will be more
likely to develop contralateral disease.
Study Design: Cohort study; Level of evidence, 3.
Methods: Patients diagnosed with idiopathic adhesive capsulitis were treated with a single intra-articular glenohumeral injection of
local anesthetic and corticosteroid as well as 4 weeks of supervised physical therapy (PT). Patients were re-evaluated monthly and
received additional conservative treatment based on failure to restore normal motion. Patient-reported outcome scores and range
of motion were used to assess treatment efficacy.
Results:Minimum 2-year follow-up data (mean, 3.4 years) were available for 60 of 75 eligible patients (80%). Patients who did not
attend supervised PT as prescribed were more likely to undergo repeat injection due to a lack of adequate range of motion at
follow-up (P ¼ .003). Conservative therapy failed in 2 patients (3.3%), and they underwent arthroscopic release and manipulation
under anesthesia. Twenty-two patients (36.7%) were subsequently diagnosed with contralateral idiopathic adhesive capsulitis,
with a higher incidence in patients with diabetes (P ¼ .009) and patients younger than 50 years (P ¼ .005). American Shoulder and
Elbow Surgeons score improved from 41.2 (95%CI, 33.0-49.4) at baseline to 92.0 (95%CI, 88.4-95.6) at final follow-up (P< .0001).
Patients with diabetes had a decrease in Shoulder Activity Scale score at final follow-up (P ¼ .049).
Conclusion: Conservative treatment for idiopathic adhesive capsulitis resulted in good clinical outcomes with a low incidence of
surgical intervention. Physical therapy reduced the use of a second injection as part of treatment in this treatment algorithm. Young
patients and patients with diabetes may be more likely to develop contralateral disease.
Keywords: idiopathic adhesive capsulitis; frozen shoulder; conservative treatment; physical therapy; corticosteroid injection
Idiopathic adhesive capsulitis, also called “frozen
shoulder,” is a common condition of unknown origin in
which contracture of the rotator interval and capsular
thickening result in shoulder pain, decreased capsular vol-
ume, and global loss of motion without other identifiable
shoulder abnormality.36 The natural history of this condi-
tion has been classically described as occurring in 3 distinct
clinical phases17,27: (1) painful “freezing” stage, lasting
approximately 3 to 9 months, during which range of motion
progressively becomes more restricted; (2) second “frozen”
stage, characterized by stiffness lasting approximately 4 to
12 months; and (3) “thawing” phase, in which range of
motion begins to improve, lasting between 1 and 4 years.
However, because these stages exist as a continuum of
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disease, it is often difficult to distinguish between these
phases in the clinical setting. The overall disease incidence
is 3% to 5%, with a peak incidence between the ages of
35 and 65 years and a slight female predominance.14,23
Patients with diabetes are at an increased risk of develop-
ing idiopathic adhesive capsulitis and have a higher rate of
nonoperative treatment failure compared with nondiabetic
patients.2,31
Although idiopathic adhesive capsulitis was tradition-
ally thought to be a self-limited disease with a duration of
approximately 2.5 years when untreated,35 recent studies
have suggested that pain and motion limitation can persist
for longer than 7 years. Furthermore, it is thought that up
to 40% of patients may have some degree of permanent
loss of motion.7,45 The greatest improvement occurs
following early treatment of this condition, which can has-
ten resolution of symptoms sooner than if the condition is
not treated.16,28,44-46 This condition is most frequently
treated conservatively with a combination of anti-
inflammatory medications, home exercises, physical
therapy,10,15,36 and glenohumeral intra-articular cortico-
steroids.31,34,38 Operative treatment consisting of manip-
ulation under anesthesia with or without arthroscopic
capsular release may be considered if patients do not
improve with nonoperative measures.42
Although idiopathic adhesive capsulitis is one of the
most common conditions treated by orthopaedic surgeons,
consensus is lacking regarding the optimal nonoperative
treatment protocol.27 Although it is universally agreed
that the first-line therapies are nonoperative, surgeons
and the existing literature disagree on which conservative
treatments are most effective.46 Additionally, the risk fac-
tors associated with the development of contralateral dis-
ease are not well-studied. Therefore, the purpose of this
study was to report outcomes following a conservative
treatment protocol for idiopathic adhesive capsulitis and
to report factors associated with outcomes and the inci-
dence of contralateral disease. We hypothesized that older
patients, who experience a decrease in shoulder activity
with increasing age,18 and patients with diabetes will be
more likely to develop contralateral disease.
METHODS
In this institutional review board–approved study, prospec-
tively collected data were analyzed to assess outcomes in a
cohort of patients being treated with a conservative treat-
ment regimen for idiopathic adhesive capsulitis. At the
clinic of a single academic sports medicine and shoulder
fellowship–trained orthopaedic surgeon (R.H.B.), all new
patients treated with a chief complaint of shoulder pain
underwent a complete history, physical examination, and
review of a standard 4-view shoulder radiographic series
obtained at the initial clinic visit. A diagnosis of idiopathic
adhesive capsulitis was made by physical examination
demonstrating a deficit of at least 60 in total active range
of motion in the affected shoulder or a deficit of at least 30
in active range of motion in 1 or more of the movements
including forward flexion, abduction, external rotation, or
internal rotation at 90 of shoulder abduction compared
with the contralateral unaffected shoulder.4 Total active
range of motion was defined as the sum of active forward
flexion, abduction, external rotation, and internal rotation
at 90 of shoulder abduction.4 For patients presenting with
bilateral idiopathic adhesive capsulitis, range of motion
was compared with age- and sex-matched normal motion
in asymptomatic patients.6
Patients were included in the study if they were diag-
nosed with idiopathic adhesive capsulitis without a history
of prior injury or surgery on the affected shoulder. Patients
were excluded if they were diagnosed with any other iden-
tifiable shoulder abnormality based on history, physical
examination, or imaging at the time of the initial clinic
visit, at any subsequent clinic visit, or on follow-up ques-
tionnaire. Patients were also excluded if they presented in
the “thawing” phase of idiopathic adhesive capsulitis,17,27 if
they were non-English-speaking, or if they had prior stroke
with residual upper extremity deficit, neuromuscular dis-
order affecting ipsilateral upper extremity, or any ipsilat-
eral shoulder disorder other than idiopathic adhesive
capsulitis. If patients had bilateral symptoms, then the
more severely affected shoulder was included in the pri-
mary analysis and the less severely affected shoulder was
excluded.
Treatment consisted of a single landmark-guided (with-
out imaging) intra-articular injection into the glenohum-
eral joint of 4 mL of 1% lidocaine, 4 mL of 0.5%
bupivacaine, and 80 mg of methylprednisolone acetate by
the senior author (R.H.B.) in the clinic at the time of diag-
nosis. Patients were given a 4-week prescription for a stan-
dardized supervised physical therapy (PT) protocol for
aggressive range of motion emphasizing external and inter-
nal rotation, posterior capsule stretching, rotator cuff and
deltoid isometrics, and a stabilization program for rotator
cuff, deltoid cuff, and scapula. No patients had received any
prior injections or had undergone PT prior to the initial
clinic visit when the diagnosis of idiopathic adhesive cap-
sulitis was made. Patients were re-evaluated at monthly
follow-up visits and, depending on their response to treat-
ment, were prescribed additional supervised PT, received a
second, fluoroscopically guided glenohumeral joint injec-
tion, or were converted to a home exercise program (Figure
1). Patients who had a persistent deficit of 60 or more were
indicated for a second corticosteroid injection. Patients with
a deficit less than 60 but more than 30 typically were
offered additional supervised PT, while those with a deficit
less than 30 were encouraged to transition to a home exer-
cise program.
All patients who received a second, fluoroscopically
guided injection were prescribed additional supervised PT
after the second injection. A landmark-guided injection was
used initially because there is insufficient evidence to jus-
tify the increased cost and inconvenience associated with
image-guided injections given the lack of clearly defined ben-
efit in terms of increased accuracy.1,20,21,25,40,43,46 If patients
do not improve after a landmark-guided injection and super-
vised PT, then a second, fluoroscopically guided glenohum-
eral joint injection followed by additional supervised PT is
administered. At this point in the algorithm, a
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fluoroscopically guided injection is used because it is
unlikely to be less accurate than a landmark-guided
injection1,20,21,40,43,46 and because we believe it is impor-
tant to exhaust nonoperative therapies before considering
surgical intervention. If no improvement is seen after 4 to
6 months of nonoperative treatment, including 2 gleno-
humeral joint injections and at least 2 full courses of PT,
then surgical intervention is offered.
Bilateral passive and active shoulder range of motion in
forward flexion, abduction, external rotation, and internal
rotation was assessed by a certified physical therapist at
the initial clinic visit at the time of diagnosis and at each
subsequent clinic visit, as well as at each PT session. Shoul-
der range of motion at the time of each follow-up clinic and
PT session was compared with range of motion at the time
of diagnosis. Successful treatment thresholds were defined
as active and passive elevation of 160, active and passive
external rotation of 45, and active internal rotation to
T10.4 The amount of time until this range of motion was
restored was calculated. Disease recurrence was defined as
loss of range of motion in the ipsilateral shoulder following
documented improvement as detailed above.4 Time to dis-
ease recurrence was based on the amount of time elapsed
between the initial clinic visit and the follow-up visit when
recurrence was diagnosed and treated. Time to diagnosis of
contralateral idiopathic adhesive capsulitis was based on
the amount of time elapsed between the initial clinic visit
and the follow-up visit when contralateral disease was
diagnosed and treated.
At minimum 2-year follow-up, all patients completed the
American Shoulder and Elbow Surgeons (ASES) Shoulder
Score29 and the Shoulder Activity Scale (SAS).8 The SAS is
validated to reliably assess the activity of patients with
shoulder disorders, allows for functional assessment of
response to treatment, and has been suggested as a
relevant variable for patients with idiopathic adhesive
capsulitis.8,22 The ASES Standardized Shoulder Assess-
ment Form is a valid, reliable measure of outcomes for
patients with shoulder dysfunction.29 All patients also com-
pleted a supplemental questionnaire regarding recurrent
symptoms, subsequent surgery on the affected shoulder,
repeat injections, and the development of contralateral
adhesive capsulitis. Eligible patients were mailed packets
containing the ASES, SAS, and supplemental question-
naires, and if these were not completed and returned, then
2 separate attempts were made to contact each patient. If
the patient declined or was unavailable for participation, he
or she was considered lost to follow-up. The final analysis
excluded patient-reported outcome scores for patients in
whom conservative treatment failed and who underwent
arthroscopic release and manipulation under anesthesia,
as this study aimed to assess outcomes after a conservative
treatment protocol rather than outcomes after surgical
management.
Figure 1. Treatment algorithm. MUA, manipulation under anesthesia; PT, physical therapy.
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Mean ASES and SAS scores at follow-up were compared
with baseline by use of paired t tests. Baseline, follow-up,
and changes in ASES and SAS scores were compared by age
(<50 vs 50 years), sex, body mass index (BMI) (<30 vs
30), and diagnosis of diabetes mellitus, a risk factor for
idiopathic adhesive capsulitis,46,48 by use of Mann-Whitney
U tests. Fisher exact tests were used to compare incidence
of contralateral symptoms by age, sex, BMI, and diagnosis
of diabetes mellitus. Statistical significance was deter-




A total of 75 patients were diagnosed with idiopathic adhe-
sive capsulitis and met eligibility criteria. Nine patients
(12%) refused participation, and 6 (8%) were lost to
follow-up. Minimum 2-year follow-up data (mean, 3.4
years; range, 2.0-5.75 years) were collected on 60 patients
(80.0%). The mean age was 52.6 years (range, 35-73 years)
and mean BMI was 28.3 (range, 19.2-61.8) (Table 1).
Nine of the 60 patients (15.0%) had a diagnosis of diabe-
tes mellitus at initial presentation, 8 of these (88.9%) with
type 1 diabetes. Themean age of patients with diabetes was
49.6 years (range, 35-73 years) compared with 53.1 years
(range, 40-72 years) for nondiabetic patients (P ¼ .15).
Overall, the mean duration of shoulder pain prior to pre-
sentation was 5.3 months (95% CI, 4.3-6.3 months). Three
patients (5.0%), all female, were diagnosed with bilateral
idiopathic adhesive capsulitis at the initial clinic visit.
There was a trend toward patients with diabetes being
more likely to have bilateral symptoms at initial presenta-
tion compared with patients without diabetes (22.2% vs
1.9%; P ¼ .056).
Glenohumeral Joint Injections
All 60 patients (100%) underwent a landmark-guided gle-
nohumeral joint injection at the initial clinic visit when the
diagnosis was established. Twenty patients (33.3%)
received a second glenohumeral joint injection under fluo-
roscopic guidance. Every patient who did not attend super-
vised PT as prescribed at the time of initial diagnosis
returned to the office with persistent deficits in shoulder
range of motion and received a fluoroscopically guided gle-
nohumeral joint injection. Patients who did not attend
supervised PT as initially prescribed were more likely to
undergo repeat glenohumeral joint injection than those
who completed the prescribed PT (100% vs 27.3%; P ¼
.003). Fluoroscopically guided injections were performed
at a mean of 57.4 days (95% CI, 46.9-67.8 days) after the
first landmark-guided glenohumeral joint injection. No
patients received a third glenohumeral joint injection. No
significant difference was noted in the incidence or timing
of a second glenohumeral joint injection based on age (<50
vs 50 years), sex, BMI (<30 vs 30), or diagnosis of dia-
betes mellitus (Table 2). There was a nonsignificant trend
toward patients with diabetes being more likely to receive a
second injection (55.6% vs 29.4%; P ¼ .15).
Treatment Failure and Recurrence
Conservative therapies, including supervised PT and 2 intra-
articular corticosteroid injections (the first landmark guided
and the second fluoroscopically guided) failed in 2 patients
(3.3%); these patients underwent arthroscopic capsular
release and manipulation under anesthesia at 6.5 and 12.6
months after diagnosis, respectively, without symptom recur-
rence at final follow-up. These patients were both nondiabetic
females 50 years or older with BMI less than 30. One of them
developed contralateral symptoms that responded to conser-
vative treatment. No additional patients underwent surgical
intervention.
Only 1 patient had ipsilateral recurrence after meeting
the threshold for successful treatment.4 This patient met
the threshold for successful treatment at 38 days after the
initial injection; then she had a second injection after recur-
rence andmet the threshold for successful treatment again,
at 33 days after the second injection. She had no subse-








<50 y 39 (65.0)





Diabetes mellitus 9 (15.0)
No diabetes 51 (85.0)
TABLE 2
Characteristics of Patients Undergoing




Age <50 y 33.3 .999
Age 50 y 33.3
Body mass index <30 28.2 .27
Body mass index 30 42.9
Diabetes mellitus 55.6 .15
No diabetes 29.4
Attended physical therapy 27.3 .003
Did not attend physical therapy 100
aPercentagesarebasedon theentire sampleof60patients.Of this
sample, 20 (33.3%) patients underwent a second glenohumeral joint
injection. Bolded value indicates statistical significance (P < .05).
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Range of Motion
Forty-nine patients (81.7%) met range of motion thresholds
for successful treatment,4 regaining motion at a mean of
76.6 days (95% CI, 59.9-93.4 days) after initial diagnosis
and glenohumeral joint injection. Nine patients (15.0%) did
not have follow-up range of motion data, but none of these
patients underwent subsequent injections, PT, or surgery
or saw another physician for shoulder pain following initial
diagnosis and treatment.
Patient-Reported Outcomes
Patients with available baseline ASES and SAS scores were
similar to those providing final follow-up with respect to
sex, age, BMI, and diabetes status. A difference was found
in baseline ASES scores in male compared with female
patients (95% CI, 44.5-58.7 vs 24.5-45.5; P ¼ .017) (Table
3). No significant differences were found in baseline ASES
scores based on age (<50 vs 50 years), BMI (<30 vs 30),
or diagnosis of diabetes mellitus.
The ASES score at final follow-up was higher compared
with baseline (95% CI, 88.4-95.6 vs 33.0-49.4; P < .0001).
We noted a higher final ASES score in patients 50 years or
older compared with those younger than 50 years (95% CI,
91.6-98.0 vs 83.1-91.3; P ¼ .006). A trend was noted toward
lower final ASES scores among patients with diabetes (95%
CI, 81.3-88.9 vs 89.8-96.8; P¼ .06). Themean ASES score at
final follow-up for patients who did not have follow-up
range of motion data to assess for treatment success4 was
similar to the mean score for patients who did meet range of
motion thresholds for treatment success (95% CI, 90.0-95.2
vs 88.0-95.7; P  .999).
Themean baseline SAS score was 10.7 (95%CI, 9.6-11.8).
No significant differences were found in baseline SAS score
based on age, sex, BMI, or diagnosis of diabetes mellitus. At
final follow-up, the SAS score was higher among male
compared with female patients (95% CI, 10.8-12.6 vs 6.4-
8.4; P < .0001) (Table 4). The mean SAS score at final
follow-up for patients who did not have follow-up range of
motion data to assess for treatment success4 was similar to
the mean score for patients who did meet did meet range of
motion thresholds for treatment success (95% CI, 8.2-10.7
vs 7.8-10.1; P ¼ .92). No significant difference was found
between pre- and posttreatment SAS score overall or
according to sex, age, BMI, or diagnosis of diabetes
mellitus.
Contralateral Adhesive Capsulitis
Twenty-two patients (36.7%) were subsequently diagnosed
with idiopathic adhesive capsulitis in the contralateral
shoulder, with a higher incidence in patients with diabetes
(77.8% vs 29.4%; P ¼ .009) and in patients younger than
50 years (61.9% vs 23.1%; P ¼ .005). Patients with contra-
lateral disease presented at a mean time of 2.0 years
(range, 0-5.0 years; 95% CI, 1.2-2.8 years) following their
initial diagnosis.
DISCUSSION
This study of a conservative treatment protocol for idio-
pathic adhesive capsulitis demonstrated clinically signifi-
cant improvements, a low rate of treatment failure
warranting surgical intervention, a low rate of ipsilateral
recurrence, and a moderate rate of contralateral disease.
Contralateral disease was more likely in patients with dia-
betes and those younger than 50 years. Patients had clini-
cally significant improvements in ASES scores, with higher
TABLE 3
American Shoulder and Elbow Surgeons (ASES) Scores
ASES Score, mean ± 95% CI P Value
At baseline
Overall cohort 41.2 ± 8.2
Male 51.6 ± 7.1 .017
Female 31.5 ± 7.0
Age <50 y 37.6 ± 8.6 .40
Age 50 y 43.2 ± 8.1
Body mass index <30 43.2 ± 9.1 .57
Body mass index 30 38.6 ± 7.2
Diabetes mellitus 33.3 ± 8.4 .44
No diabetes 42.7 ± 8.2
At follow-up
Overall cohort 92.0 ± 3.6
Male 95.4 ± 1.7 .25
Female 89.5 ± 4.5
Age <50 y 87.2 ± 4.1 .006
Age 50 y 94.8 ± 3.2
Body mass index <30 93.9 ± 2.9 .19
Body mass index 30 88.7 ± 4.6
Diabetes mellitus 85.1 ± 3.8 .06
No diabetes 93.3 ± 3.5
TABLE 4
Shoulder Activity Scale (SAS) Scores
SAS Score, mean ± 95% CI P Value
At baseline
Overall cohort 10.7 ± 1.1
Male 11.9 ± 1.0 .19
Female 9.5 ± 1.1
Age <50 y 9.6 ± 1.1 .37
Age 50 y 11.3 ± 1.1
Body mass index <30 11.8 ± 1.3 .18
Body mass index 30 9.3 ± 0.7
Diabetes mellitus 11.5 ± 1.0 .84
No diabetes 10.5 ± 1.1
At follow-up
Overall cohort 9.2 ± 1.1
Male 11.7 ± 0.9 <.0001
Female 7.4 ± 1.0
Age <50 y 9.3 ± 1.1 .87
Age 50 y 9.2 ± 1.1
Body mass index <30 9.8 ± 1.1 .11
Body mass index 30 8.3 ± 1.2
Diabetes mellitus 8.6 ± 1.4 .44
No diabetes 9.3 ± 1.1
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ASES scores in patients 50 years and older. Patients who
did not attend supervised PT after initial diagnosis were
more likely to receive a second glenohumeral joint cortico-
steroid injection.
This treatment protocol resulted in a low rate of treat-
ment failure requiring operative intervention (3.3%) when
compared with previously reported rates in the literature,
which range from 7% to 28%.15,26,36 Before considering
surgical intervention, we advocate an exhaustive trial of
conservative treatment as outlined by our treatment algo-
rithm. Substantially higher rates of conservative treat-
ment failure warranting operative intervention than
those reported in the present study may indicate over-
treatment of this condition. As such, surgeons considering
operative intervention must be sure to have exhausted
nonoperative treatment options. Higher rates of contralat-
eral disease in patients younger than 50 years and in
patients with diabetes have not been previously described,
although diabetes has been associated with a higher over-
all risk of developing this disorder.46,48 Why patients who
develop this disorder before the age of 50 have a higher
risk for contralateral disease deserves further study. A
higher incidence of subsequent corticosteroid injections
among patients who did not attend supervised PT sug-
gests that therapy is an important aspect of the treatment
protocol.
In a previous study, we demonstrated that patients with
idiopathic adhesive capsulitis have similar shoulder activ-
ity levels compared with age- and sex-matched controls
without shoulder problems.22 In the present study, conser-
vative treatment was not associated with a decrease in
activity level among most patients, suggesting that most
were able to return to the activity level that they had prior
to developing adhesive capsulitis. We anticipated that idi-
opathic adhesive capsulitis would be more likely to develop
in less active patients. Our hypothesis that older patients
would be more likely to develop contralateral idiopathic
adhesive capsulitis was largely based on a previous study
demonstrating a decrease in shoulder activity level with
increasing age18; however, that study evaluated healthy
controls rather than patients with idiopathic adhesive
capsulitis. According to our previous study, which used
the same cohort of patients as the present study, older
male patients with this condition had higher shoulder
activity levels compared with younger patients and female
patients.22 In the present study, we found that older
patients were less likely to develop contralateral idio-
pathic adhesive capsulitis. As such, it is possible that
patients with higher shoulder activity levels are also less
likely to develop this condition in the contralateral shoul-
der. However, further study is needed to better assess the
association between shoulder activity level and the devel-
opment of this disorder.
Several studies have reported outcomes following vari-
ous nonoperative therapies for adhesive capsulitis.
Although intra-articular corticosteroid injections are fre-
quently used, results following these injections have been
mixed.46 Two randomized controlled trials (RCTs) demon-
strated no significant benefit in favor of corticosteroid injec-
tions alone compared with PT alone.3,13 However, the
majority of studies have suggested a short- to mid-term
benefit in terms of pain reduction and improved range of
motion in patients after corticosteroid injection compared
with various control groups, including those undergoing
just PT or home exercises.‡ Two RCTs demonstrated that
adding an intra-articular corticosteroid injection to PT
leads to better outcomes than PT alone.12,38 Most studies
have described a clinically significant positive effect in pain
relief, motion, and patient-reported outcomes between 2
and 24 weeks following injection compared with other non-
operative therapies.46 The injection may relieve pain in the
short to mid term while also facilitating less painful PT
sessions to help expediently restore a functional range of
motion.
Our findings suggest that PT is an important component
of a conservative treatment protocol, as PT decreased the
likelihood of receiving a second injection from 100% to
27.3%. We emphasize the importance of supervised PT to
patients, as the exercises in the protocol can be difficult for
them to perform on their own as part of a home program. In
particular, we have found that passive range of motion
exercises and posterior capsular stretching are best ini-
tially performed under the guidance of a licensed physical
therapist. Furthermore, in our experience, supervised PT
improves patient compliance compared with a home pro-
gram without any supervised PT. After patients have
achieved successful treatment thresholds,4 they are transi-
tioned to a home therapy program as part of our treatment
protocol. However, aside from a significant difference in the
number of second glenohumeral joint injections, no signif-
icant differences were found in patient-reported outcomes
comparing those who did and did not initially attend super-
vised PT as prescribed.
Several studies have examined the accuracy of
landmark-guided injections and image-guided injections
within the glenohumeral joint, reporting a relatively wide
range of accuracy for both types. Landmark-guided injec-
tions have a reported accuracy of 45% to 98%,20,21,40,43
while image-guided injections have a reported accuracy of
63% to 100%.1,46 Interestingly, multiple studies have
reported an accuracy of greater than 90% for landmark-
guided injections alone.20,21,40 Only 1 study investigated
the efficacy of ultrasound- versus landmark-guided injec-
tions for adhesive capsulitis, demonstrating improved pain
relief and range of motion only within the first 2 weeks
following ultrasound-guided injection, after which no sig-
nificant differences were noted in any outcome measures.25
Furthermore, studies have demonstrated no difference in
pain or range of motion when comparing intra-articular
and subacromial injections, suggesting that landmark-
guided injections that miss the glenohumeral joint may still
be effective.32,37,41 Currently, insufficient evidence is avail-
able to justify the increased cost associated with image-
guided injections for the initial treatment of idiopathic
adhesive capsulitis, considering the lack of apparent bene-
fit in terms of increased accuracy.46
‡References 5, 9, 11, 12, 19, 24, 33, 38, 39, 47.
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This study has several limitations. First, this was a
single-center, single-surgeon study at an academic medi-
cal center, and thus the results may not be generalizable to
all patient populations. Idiopathic adhesive capsulitis was
diagnosed clinically based on history, physical examina-
tion, and normal shoulder radiographs. Although distinct
stages of idiopathic adhesive capsulitis have been
described, the definition of this condition, including the
number of stages, descriptions of each stage, and the dura-
tion of each stage, varies among reports.17,27,30,49 As the
clinical presentation of these stages can overlap, we did
not believe that we could accurately distinguish between
the “freezing” and “frozen” stages of idiopathic adhesive
capsulitis and therefore did not specifically assess how
each stage of disease related to treatment outcomes. Fur-
ther study is required to determine how the various stages
of disease respond to this treatment protocol.
Also, because no single, widely accepted definition of idi-
opathic adhesive capsulitis is available, we used the best
available definition as previously described in a level 1
study.4 Although a standardized PT protocol was pre-
scribed, supervised PT was not performed at a single insti-
tution by a single therapist but rather was provided by a
certified physical therapist at a location of the patient’s
choosing, which reflects clinical reality and makes the find-
ings more generalizable. This study did not include a con-
trol group, and all patients were treated with the same
protocol. A subset of patients did not return for final range
of motion assessment, and therefore we could not assess
motion thresholds for treatment success4 in these patients.
However, no differences were noted in patient-reported
outcome scores, and none of these patients underwent sub-
sequent PT or surgery, received subsequent injections,
reported symptom recurrence, or saw another provider for
shoulder pain. Finally, the study may have been underpow-
ered to demonstrate significant associations of ASES and
SAS scores with certain demographic and patient-specific
risk factors, and no previous study has established minimal
clinically important differences for ASES and SAS scores in
this disease process.
CONCLUSION
At a minimum 2-year follow-up, patients with idiopathic
adhesive capsulitis treated conservatively with 1 or
more intra-articular glenohumeral joint corticosteroid
injections and supervised PT demonstrated clinically
significant improvements in shoulder range of motion,
pain, and function; a low rate of conservative treatment
failure warranting surgical intervention; a low inci-
dence of ipsilateral recurrence; and a moderate rate of
contralateral disease. Patients who did not initially
attend supervised PT were more likely to receive a sec-
ond intra-articular injection, suggesting that PT has an
important role in the treatment of adhesive capsulitis.
Finally, patients with diabetes and younger patients
may be more likely to develop contralateral idiopathic
adhesive capsulitis.
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